Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 310-057-6 | CAS number: 102110-55-4 A complex combination of hydrocarbons obtained by the distillation of the products of steam cracking or similar processes after taking off the very light products resulting in a residue starting with hydrocarbons having carbon numbers greater than C5. It consists predominantly of aromatic hydrocarbons having carbon numbers greater than C5 and boiling above approximately 40°C (104°F).
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://poisoncentres.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Immunotoxicity
Administrative data
- Endpoint:
- immunotoxicity: short-term inhalation
- Type of information:
- migrated information: read-across based on grouping of substances (category approach)
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Guideline study, GLP status not known, published in peer reviewed literature, fully adequate for assessment
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- publication
- Title:
- Oral gavage subchronic neurotoxicity and inhalation subchronic immunotoxicity studies of ethylbenzene in the rat.
- Author:
- Li, AA, Maurissen, JPJ, Barnett, JF, Foss, J, Freshwater, L, Garman, RH, Peachee, VL, Hong, SJ, Stump, DG and Bus, JS.
- Year:
- 2 010
- Bibliographic source:
- NeuroToxicology, 31, 247-258.
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.7800
- Principles of method if other than guideline:
- T-cell dependent antibody responses (assessed using a splenic antibody-forming cell assay) were determined in female rats exposed to ethylbenzene by inhalation for 28-days. The assay measures the activity of IgM antibody-forming cells against sheep red blood cells.
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Ethylbenzene
- EC Number:
- 202-849-4
- EC Name:
- Ethylbenzene
- Cas Number:
- 100-41-4
- Molecular formula:
- C8H10
- IUPAC Name:
- ethylbenzene
- Reference substance name:
- 101-41-4
- IUPAC Name:
- 101-41-4
- Details on test material:
- Ethylbenzene, 99.96% pure by GC-FID, was supplied by The Dow Chemical Company, Midland, MI via Ashland Chemical, Morrisville, PA.
Constituent 1
Constituent 2
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD(SD)
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories Inc., Raleigh, NC USA
- Age at study initiation: approx. 45 d
ENVIRONMENTAL CONDITIONS
- Animals maintained in AAALAC International accredited facilities in accordance with US-NRC (1996) guidelines.
Administration / exposure
- Route of administration:
- inhalation: vapour
- Vehicle:
- air
- Details on exposure:
- EXPOSURE CONDITIONS
Animals housed individually in stainless steel-glass inhalation chambers (volume = 2 m3) and exposed (whole body) 6 hr/d for 28 consecutive days.
SELECTION OF DOSE LEVELS:
The highest dose level (500 ppm, equivalent to 2.175 mg/l) was selected based on earlier reproduction and developmental neurotoxicity studies. In addition, EPA OPPTS 870.7800 guideline recommends that the high dose should not exceed 2 mg/l. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Achieved exposure concentration confirmed using GC-FID (no further details).
- Duration of treatment / exposure:
- 28-d
- Frequency of treatment:
- daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 25, 100 and 500 ppm
Basis:
nominal conc.
nominal in air
- No. of animals per sex per dose:
- 10 (females only)
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- IMMUNISATION WITH SHEEP RED BLOOD CELLS:
Animals were immunized using sheep red blood cells (sRBC; 2 x 10^8 cells in 0.5 ml Earle's Balanced Salt Solution; EBSS) administered by daily injection into a lateral tail vein on the 4 days prior to sacrifice.
Examinations
- Observations and clinical examinations performed and frequency:
- CAGE SIDE OBSERVATIONS:
Animals were observed at least twice daily before and after exposure.
BODY WEIGHT and FOOD CONSUMPTION:
Data collected twice weekly for the duration of the study. - Sacrifice and pathology:
- NECROPSY PROCEDURES:
Animals were euthanized by carbon dioxide inhalation.
Blood was collected from the vena cava for haematological evaluation.
Organ weight data were collected for: brain, kidney, liver, lung, spleen, thymus.
The spleens were removed, placed in EBSS with 15mM HEPES supplemented with gentamicin, and single cell suspensions prepared. - Cell viabilities:
- PREPARATION OF SPLEEN CELL SUSPENSIONS:
Splenocyte viability was determined using propidium iodide staining and flow cytometry (no further details) - Specific cell-mediated immunity:
- SPLENIC ANTIBODY-FORMING CELL (AFC) ASSAY
The AFC assay was performed using a modification of the Jerne plaque assay (Jerne, NK et al. (1963) In Amos et al. (eds) "Cell Bound Antibodies", Wistar Institute Press, Philadelphia, PA) (no further details).
The AFC data were expressed as specific activity (IgM AFC/10^6 spleen cells) and total spleen activity (IgM AFC/spleen). - Positive control:
- POSITIVE CONTROL SUBSTANCE:
- cyclophosphamide (50 mg/kg) given by daily i.v. injection on the 4 d immediately prior to sacrifice. - Statistics:
- Body weight change, food consumption, haematology data and organ weights were analysed using one-way ANOVA with Dunnett's test. The AFC assay data were tested for homogeneity of variances using Bartlett’s Chi Square test, with homogenous data evaluated using ANOVA followed by Dunnett's test. Non-homogenous data were analysed a non-parametric ANOVA followed by Gehan-Wilcoxon test. Dose-related trends were identified using Jonckheere's test. The positive control group was compared to the vehicle control group using Student's T-test.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Haematological findings:
- no effects observed
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- liver and spleen weights increased
- Details on results:
- GENERAL OBSERVATIONS AND CLINICAL SIGNS:
All animals survived to scheduled necropsy, with no adverse test substance-related clinical signs noted.
BODY WEIGHTS:
Body weight unaffected by treatment; body weight decreased by 16% in positive control group.
FOOD CONSUMPTION:
Food consumption unaffected by treatment (data not reported).
HAEMATOLOGY
Haematology parameters unaffected by treatment (data not reported); white cell and platelet counts, mean corpuscular concentration, absolute and percent lymphocyte and neutraphil counts all decreased in positive control group (data not reported).
ORGAN WEIGHTS:
Liver and kidney weights increased in the 500 ppm treatment group, brain lung, spleen and thymus weights unremarkable.
Selected results by treatment level for female rats exposed to 0, 25, 100 and 500 ppm ethylbenzene or 50 mg/kg bw/d cyclophosphamide:
Absolute spleen weight (mg): 610, 548, 539, 562, 271 **
Relative spleen weight (mg/100 g bw): 0.25, 0.24, 0.23, 0.25, 0.13 **
Absolute thymus weight (mg): 486, 424, 455, 432, 107 **
Relative thymus weight (mg/100 g bw): 0.20, 0.19, 0.20, 0.19, 0.05 **
*** P<0.01 (Dunnet's test; effects present only in positive control group)
SPLENIC ANTIBODY-FORMING CELL ASSAY:
No treatment-related effects on spleen cell number or IgM AFC response to T-cell dependent antigen sRBC, whereas specific and total IgM AFC clearly and significantly reduced after cyclophosphamide treatment.
Results by treatment level for female rats exposed to 0, 25, 100 and 500 ppm ethylbenzene or 50 mg/kg bw/d cyclophosphamide:
Spleen cells (x10^7 per spleen): 78.7, 66.0, 63.8, 67.9, 9.7**
Specific activity - IgM AFC/10^6 spleen cells: 1473, 1546, 1718, 2145, 40 **
Total activity - IgM AFC/10^3 per spleen: 1134, 1027, 1168, 1462, 4 **
***P<0.01 (Dunnet's test; effects present only in positive control group)
Specific immunotoxic examinations
- Cell viabilities:
- no effects observed
- Specific cell-mediated immunity:
- no effects observed
Effect levels
- Dose descriptor:
- NOAEC
- Effect level:
- 500 ppm (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: no effect on the activity of IgM antibody-forming cells present in spleen at the highest dose level tested.
Applicant's summary and conclusion
- Conclusions:
- Exposure to up to 500 ppm ethylbenzene vapour for 28-d did not affect the humoral component of the rat immune system.
- Executive summary:
Female SD rats, age approx. 7 weeks, were exposed (whole body) to ethylbenzene vapour (0, 25, 125 and 500 ppm) for 28-d and humoral immune function determined using splenic antibody-forming cell (AFC) plaque-forming assay following sensitisation of the animals to sheep red blood cells (sRBC). A positive control group received cyclophosphamide.The assay assesses the interaction of complement and antibodies (produced in response to immunization) that is directed against sRBC. The study design and conduct was OPPTS 870.7800 compliant, with the results providing a measure of the effect of ethylbenzene on humoral immune responses. The results showed that spleen and thymus weights from ethylbenzene-exposed animals were unremarkable, with no treatment-related effects on spleen cell number or IgM AFC responses in sRBC-sensitised animals. In contrast spleen and thymus weights, together with specific and total IgM AFC, were clearly and significantly reduced after cyclophosphamide treatment. The results demonstrate that sub-acute exposure to up to 500 ppm ethylbenzene vapour for 28 -d was without effect on the humoral component of the rat immune system.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)